XstalBio Ltd signs a licence agreement with Boehringer Ingelheim Pharma GmbH &Co. KG for its protein formulation and drug delivery technology
XstalBio is a Glasgow-based company specialising in the formulation of protein-based drugs into particles that can be engineered for advanced drug delivery applications. XstalBio has signed a licence agreement with Boehringer Ingelheim Pharma GmbH & Co.KG, one of the world’s leading biopharmaceutical companies for its pioneering protein-coated microcrystal (PCMC) technology. As part of the agreement, XstalBio will receive milestone payments and manufacturing rights to the jointly developed manufacturing process.
A spin-out in 2004, from the Universities of Strathclyde and Glasgow, XstalBio’s platform technology allows a wide range of protein-based drugs to be formulated for parenteral, transdermal and pulmonary delivery.
Dr. Marie-Claire Parker, CEO, at XstalBio said
“We are delighted to enter into this collaboration with Boehringer Ingelheim, a world recognised player in the biotechnology arena. This agreement, marks a significant milestone in the development of XstalBio, providing us with a strong partner in further development and endorsement of our technology”.
Dr. Helmut Hoffmann, Vice President of Process Science at Boehringer Ingelheim, said that
“ We believe this collaboration with XstalBio will provide improved methods for the formulation and delivery of biomolecules”.
XstalBio’s Chief Scientist, Dr. Barry Moore, said
“The technology provides a highly differentiated method for preparing biomolecules as stable, solid formulations, with the particles capable of being engineered for delivery in a range of formulations via various routes of administration”.
Dr. Karoline Bechtold-Peters, Associate Director Clinical Supplies and Process Transfer at Boehringer Ingelheim, said:
“Both partners will jointly develop and scale-up the PCMC technology for GMP manufacturing at Pilot scale."
ENDS
For further information please contact Dr Marie Claire Parker on Tel + 44 (0)208 515 0371
Notes to Editors
About XstalBio XstalBio specialises in the formulation of biomolecules in the form of particles engineered for advanced drug delivery. The company’s proprietary technology is applicable to proteins, peptides, nucleic acids and vaccines and has the potential to improve therapeutic value, strengthen patent cover for new biological entities and extend product life-cycles. XstalBio is commercialising the PCMC patent portfolio on a product-by-product basis and has a range of collaborations with pharmaceutical and biotechnology companies. XstalBio is based in Glasgow, having spun-out from Strathclyde and Glasgow Universities in 2004.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and almost 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending almost one fifth of net sales in its largest business segment Prescription Medicines on research and development.
Boehringer Ingelheim offers the entire production technology chain at its biopharmaceutical manufacturing facilities in Vienna (Austria), Biberach (Germany) and St. Joseph/ Missouri (USA) with additional fill-and-finish capacities in Bedford/Ohio (USA). It has the world’s largest capacities for contract manufacturing of mammalian cell culture products for biopharmaceuticals and is Europe’s leading manufacturer of biopharmaceuticals.
For more information on Boehringer Ingelheim, please visit www.boehringer-ingelheim.com.
For more information about Boehringer Ingelheim’s biopharmaceutical business, please visit Boehringer Biopharm.
